**UNITED
      STATES**


**SECURITIES
      AND EXCHANGE COMMISSION**


**Washington,
      DC 20549**




**FORM
      10-QSB/A**


**(Amendment
      No. 1)**








**x
                QUARTERLY REPORT
                PURSUANT TO SECTION 13 OR 15(d) OF THE**
              **SECURITIES
                EXCHANGE ACT OF 1934****For
                the quarterly period ended June 30, 2007****o
                TRANSITION REPORT
                PURSUANT TO SECTION 13 OR 15(d) OF THE**
              **SECURITIES
                EXCHANGE ACT**


**For
      the transition period from**______**to**______****







**Commission
      File Number: 001-33004**








**Opexa
      Therapeutics, Inc.**


(Exact
      name of Issuer as specified in its charter)








**Texas**
            **76-0333165**(State
                of Incorporation)
            (IRS
                Employer Identification No.)





**2635
      North Crescent Ridge Drive**


**The
      Woodlands, Texas 77381**


(Address
      of
      Principal Executive Offices)








**(281)
      272-9331**


Issuer’s
      Telephone Number, Including Area Code








Check
      whether the issuer (1) filed all reports required to be filed by Section 13
      or
      15(d) of the Exchange Act during the past 12 months (or for such shorter period
      that the registrant was required to file such reports), and (2) has been subject
      to such filing requirements for the past 90 days.   Yes x No o




Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act).    Yes o   No
x





Number
      of
      shares outstanding of the issuer's classes of common equity, as of November
      29,
      2007: 6,696,784 shares of common stock.





Transitional
      Small Business Disclosure Format (Check
      one):    Yes o   No
x




-1-





**OPEXA
      THERAPEUTICS, INC.**


**INDEX
      TO FORM 10-QSB**


**June
      30, 2007**




**Item**
            **Description**
            **Page**Explanatory
                Note
            1**Part
                I – FINANCIAL
                INFORMATION**Item
                1
            Balance
                Sheets as of  June 30, 2007 and
                December 31, 2006 (unaudited) (RESTATED)
            2Statements
                of Expenses for the Three and Six Months Ended
                June 30, 2007 and 2006 and the Period from January 22, 2003 (Inception)
                to
                June 30, 2007 (unaudited) (RESTATED)
              
              Statements
                of Cash Flows for the Six Months Ended June
                30, 2007 and 2006 and the Period from January 22, 2003 (Inception)to
                June
                30, 2007 (unaudited) (RESTATED)
              
              Notes
                to Financial Statements
                (unaudited)
            3
              
              4
              
              6Item
                2
            Management's
                Discussion and
                Analysis
            11Item
                3
            Controls
                and Procedures
            18**Part
                II**Item
                1
            Legal
                Proceedings
            19Item
                2
            Recent
                Sales of Unregistered
                Securities
            19Item
                3
            Defaults
                Upon Senior Securities
            19Item
                4
            Submission
                of Matters to a Vote of Security
                Holders
            19Item
                5
            Other
                Information
            20Item
                6
            Exhibits
            20Signatures
            20








***Explanatory
      Note***





We
      are
      amending our Quarterly Report on Form 10-QSB for the for the quarter ending
      June
      30, 2007 in connection with restating our consolidated financial statements
      for
      the three months and six months ended June 30, 2007 and 2006 and for the period
      January 22, 2003(Inception) to June 30, 2007.  The restatement of our
      financial statements is the result of our determination that the intangible
      assets associated with the acquisition of Opexa Pharmaceuticals, Inc., the
      University of Chicago technology license and the Shanghai Institutes for
      Biological Sciences, Chinese Academy of Sciences of the Peoples Republic of
      China technology license should have been recorded as acquired in process
      research and development.





The
      purpose of this amendment is to restate the accompanying financial statements
      for the reasons further described in Note 2 to the financial statements included
      in Item 1 (Financial Information) herein.





-1-








**PART
      I**





**FINANCIAL
      INFORMATION**





ITEM
      1.
      FINANCIAL STATEMENTS.







**OPEXA
                  THERAPEUTICS, INC.****(a
                  development stage company)****BALANCE
                  SHEETS (RESTATED)****(unaudited)****Restated**
              
              
              **Restated****June
                  30,**
              
              
              **December
                  31,****2007**
              
              
              **2006****Assets**Current
                  assets:Cash
                  and cash equivalents
              
              $
              8,918,101
              
              
              $
              12,019,914Investment
                  in marketable securities
              
              
              -
              
              
              
              2,952,096Other
                  current assets
              
              
              718,876
              
              
              
              472,881Total
                  current assets
              
              
              9,636,977
              
              
              
              15,444,891Property
                  & equipment, net accumulated depreciation of $483,275 and $395,284,
                  respectively
              
              
              1,371,007
              
              
              
              1,361,377Total
                  assets
              
              $
              11,007,984
              
              
              $
              16,806,268**Liabilities
                  and Stockholders' Equity**Current
                  liabilities:Accounts
                  payable
              
              $
              1,273,766
              
              
              $
              868,862Stock
                  payable
              
              
              112,440
              
              
              
              112,440Accrued
                  expenses
              
              
              842,995
              
              
              
              135,069Note
                  payable
              
              
              1,500,000
              
              
              
              1,500,000Current
                  maturity of loan payable
              
              
              55,928
              
              
              
              14,080Derivative
                  liability
              
              
              -
              
              
              
              6,656,677Total
                  current liabilities
              
              
              3,785,129
              
              
              
              9,287,128Long
                  term liabilities:Loan
                  payable
              
              
              191,680
              
              
              
              96,242Total
                  liabilities
              
              
              3,976,809
              
              
              
              9,383,370Commitments
                  and contingencies
              
              
              -
              
              
              
              -Stockholders'
                  equity:Convertible
                  preferred stock, no par value, 10,000,000 shares
              
              
              -
              
              
              
              -authorized,
                  none issued and outstandingCommon
                  stock, $0.50 par value, 100,000,000 shares authorized,
              
              
              3,348,351
              
              
              
              3,348,3516,696,784
                  shares issued and outstandingAdditional
                  paid in capital
              
              
              75,191,789
              
              
              
              63,118,180Deficit
                  accumulated during the development stage
              
              
              (71,508,965
              )
              
              
              (59,043,633
              )Total
                  stockholders' equity
              
              
              7,031,175
              
              
              
              7,422,898Total
                  liabilities and stockholders' equity
              
              $
              11,007,984
              
              
              $
              16,806,268


-2-


**OPEXA
                    THERAPEUTICS, INC.****(a
                    development stage company)****STATEMENTS
                    OF EXPENSES(RESTATED)****Three
                    and Six Months ended June 30, 2007 and 2006 and the****Period
                    from January 22, 2003 (Inception) to June 30, 2007****(unaudited)****Restated**
                
                
                **Restated**
                
                
                **Restated**
                
                
                **Restated**
                
                
                **Restated****Three
                    Months**
                
                
                **Three
                    Months**
                
                
                **Six
                    Months**
                
                
                **Six
                    Months**
                
                
                **Inception****Ended**
                
                
                **Ended**
                
                
                **Ended**
                
                
                **Ended**
                
                
                **through****June
                    30,**
                
                
                **June
                    30,**
                
                
                **June
                    30,**
                
                
                **June
                    30,**
                
                
                **June
                    30,****2007**
                
                
                **2006**
                
                
                **2007**
                
                
                **2006**
                
                
                **2007**Research
                    and development
                
                $
                3,712,208
                
                
                $
                1,554,912
                
                
                $
                6,959,674
                
                
                $
                2,418,362
                
                
                $
                47,645,353General
                    and administrative
                
                
                865,744
                
                
                
                3,169,832
                
                
                
                1,715,530
                
                
                
                4,245,714
                
                
                
                15,921,999Depreciation
                
                
                50,096
                
                
                
                49,596
                
                
                
                98,925
                
                
                
                72,646
                
                
                
                384,181Loss
                    on disposal of assets
                
                
                4,034
                
                
                
                -
                
                
                
                4,034
                
                
                
                362
                
                
                
                486,343Operating
                    loss
                
                
                (4,632,082
                )
                
                
                (4,774,340
                )
                
                
                (8,778,163
                )
                
                
                (6,737,084
                )
                
                
                (64,437,876
                )Interest
                    income
                
                
                141,971
                
                
                
                198,785
                
                
                
                320,794
                
                
                
                218,406
                
                
                
                1,097,015Other
                    income
                
                
                -
                
                
                
                43,065
                
                
                
                -
                
                
                
                46,450
                
                
                
                77,003Loss
                    on derivative liability
                
                
                -
                
                
                
                (3,532,348
                )
                
                
                -
                
                
                
                (3,278,208
                )
                
                
                -Interest
                    expense
                
                
                (3,691
                )
                
                
                (184
                )
                
                
                (6,144
                )
                
                
                (613
                )
                
                
                (8,245,107
                )Net
                    loss
                
                $
                (4,493,802
                )
                
                $
                (8,065,022
                )
                
                $
                (8,463,513
                )
                
                $
                (9,751,049
                )
                
                $
                (71,508,965
                )Basic
                    and diluted loss per share
                
                $
                (0.67
                )
                
                $
                (1.34
                )
                
                $
                (1.26
                )
                
                $
                (2.40
                )
                
                N/AWeighted
                    average shares outstanding
                
                
                6,696,784
                
                
                
                6,039,561
                
                
                
                6,696,784
                
                
                
                4,063,473
                
                
                N/A
  
 -3-
 
  **OPEXA
                    THERAPEUTICS, INC.****(a
                    development stage company)****STATEMENTS
                    OFCASH FLOWS(RESTATED)****Six
                    Months Ended June 30, 2007 and 2006 and the****Period
                    from January 22, 2003 (Inception) to June 30, 2007****(unaudited)****Restated**
                
                
                **Restated**
                
                
                **Restated****Six
                    Months**
                
                
                **Six
                    Months**
                
                
                **Inception****Ended**
                
                
                **Ended**
                
                
                **through****June
                    30,**
                
                
                **June
                    30,**
                
                
                **June
                    30,****2007**
                
                
                **2006**
                
                
                **2007**Cash
                    flows from operating activitiesNet
                    loss
                
                $
                (8,463,513
                )
                
                $
                (9,751,049
                )
                
                $
                (71,508,965
                )Adjustments
                    to reconcile net loss to net cashused
                    in operating activitiesStock
                    payable for services
                
                
                -
                
                
                
                
                
                
                
                112,440Stock
                    issued for acquired research and development
                
                
                -
                
                
                
                
                
                
                
                26,286,589Stock
                    issued for services
                
                
                -
                
                
                
                180,000
                
                
                
                1,861,400Stock
                    issued for debt in excess of principal
                
                
                -
                
                
                
                -
                
                
                
                109,070Amortization
                    of discount on notes payable dueto
                    warrants and beneficial conversion feature
                
                
                -
                
                
                
                -
                
                
                
                6,313,205Realized
                    gain on marketable securities
                
                
                25,912
                
                
                
                -
                
                
                
                -Loss
                    on derivative liability
                
                
                -
                
                
                
                3,278,208
                
                
                
                -Depreciation
                
                
                98,925
                
                
                
                72,646
                
                
                
                384,181Debt
                    financing costs
                
                
                -
                
                
                
                -
                
                
                
                365,910Option
                    and warrant expense
                
                
                1,415,113
                
                
                
                2,829,716
                
                
                
                10,718,657Loss
                    on disposition of fixed assets
                
                
                4,034
                
                
                
                -
                
                
                
                486,343Changes
                    in:Accounts
                    payable
                
                
                404,906
                
                
                
                (6,626
                )
                
                
                849,468Marketable
                    securities
                
                
                2,926,184
                
                
                
                -
                
                
                
                -Prepaid
                    expenses
                
                
                (245,995
                )
                
                
                (458,332
                )
                
                
                (714,006
                )Accrued
                    expenses
                
                
                707,926
                
                
                
                402,779
                
                
                
                657,667Other
                    assets
                
                
                -
                
                
                
                -
                
                
                
                (388,210
                )Net
                    cash provided by (used in) operating activities
                
                
                (3,126,508
                )
                
                
                (3,452,658
                )
                
                
                (24,466,251
                )Cash
                    flows from investing activitiesPurchase
                    of property & equipment
                
                
                (112,591
                )
                
                
                (341,314
                )
                
                
                (1,163,645
                )Disposition
                    of property & equipment
                
                
                -
                
                
                
                1,085
                
                
                
                -Net
                    cash used in investing activities
                
                
                (112,591
                )
                
                
                (340,229
                )
                
                
                (1,163,645
                )Cash
                    flows from financing activitiesCommon
                    stock sold for cash, net of offering costs
                
                
                -
                
                
                
                21,163,763
                
                
                
                26,509,412Proceeds
                    from debt
                
                
                137,286
                
                
                
                -
                
                
                
                8,102,199Repayments
                    on notes payable
                
                
                -
                
                
                
                -
                
                
                
                (63,614
                )Net
                    cash provided by financing activities
                
                
                137,286
                
                
                
                21,163,763
                
                
                
                34,547,997Net
                    change in cash and cash equivalents
                
                
                (3,101,813
                )
                
                
                17,370,876
                
                
                
                8,918,101Cash
                    and cash equivalents at beginning of period
                
                
                12,019,914
                
                
                
                2,560,666
                
                
                
                -Cash
                    and cash equivalents at end of period
                
                $
                8,918,101
                
                
                $
                19,931,542
                
                
                $
                8,918,101
  -4-
  Cash
                    paid for:Income
                    tax
                
                $
                -
                
                
                $
                -
                
                
                $
                -Interest
                
                
                -
                
                
                
                -
                
                
                
                429NON-CASH
                    TRANSACTIONSIssuance
                    of common stock to Sportan shareholders
                
                
                -
                
                
                
                -
                
                
                
                147,733Issuance
                    of common stock for accrued interest
                
                
                -
                
                
                
                -
                
                
                
                525,513Conversion
                    of notes payable to common stock
                
                
                -
                
                
                
                -
                
                
                
                6,407,980Conversion
                    of accrued liabilities to common stock
                
                
                -
                
                
                
                -
                
                
                
                197,176Conversion
                    of accounts payable to note payable
                
                
                -
                
                
                
                -
                
                
                
                93,364Discount
                    on convertible notes relating to:-
                    warrants
                
                
                -
                
                
                
                -
                
                
                
                3,309,790-
                    beneficial conversion feature
                
                
                -
                
                
                
                -
                
                
                
                1,715,973-
                    stock attached to notes
                
                
                -
                
                
                
                -
                
                
                
                1,287,440Reclassification
                    of derivative liabilities
                
                
                6,656,677
                
                
                
                -
                
                
                
                6,656,677
  -5-


**OPEXA
      THERAPEUTICS, INC.**


**(a
      development stage company)**


**NOTES
      TO FINANCIAL STATEMENTS**


**(unaudited)**




**NOTE
      1 – BASIS OF
      PRESENTATION**





The
      accompanying unaudited interim financial statements of Opexa Therapeutics,
      Inc.,
      a development stage company, have been prepared in accordance with accounting
      principles generally accepted in the United States of America and the rules
      of
      the Securities and Exchange Commission and should be read in conjunction with
      the audited financial statements and notes thereto contained in Opexa’s latest
      Annual Report filed with the SEC on Form 10-KSB. In the opinion of management,
      all adjustments, consisting of normal recurring adjustments, necessary for
      a
      fair presentation of financial position and the results of operations for the
      interim periods presented have been reflected herein. The results of operations
      for interim periods are not necessarily indicative of the results to be expected
      for the full year.  Notes to the financial statements that would
      substantially duplicate the disclosure contained in the audited financial
      statements for the most recent fiscal year as reported in Form 10-KSB, have
      been
      omitted.





**NOTE
      2**– **RESTATEMENT OF FINANCIAL STATEMENTS**





The
      Company is restating these financial statements for the three months and six
      months ended June 30, 2006 and 2007 and January 22, 2003 (Inception) to June
      30,
      2007.





Following
      is a description of the restatements:





The
      Company acquired Opexa Pharmaceuticals in October 2004 and originally accounted
      for the acquired in process research and development of $23,991,128 as
      intangible assets.  In November 2007 the Company re-evaluated its
      accounting for acquired research and development and upon further consideration
      of Paragraph 11(c) of Statement of Financial Accounting Standards No. 2 (SFAS
      No. 2) and accounting guidance from Financial Accounting Standards Board
      Interpretation No. 4 “Applicability of FASB Statement  No. 2 to
      Business Combinations Accounted for by the Purchase Method” (FIN 4), the Company
      determined that these assets did not have an alternative future use at the
      date
      of acquisition. Thus, they had no separate economic value and should be
      accordingly expensed to research and development in the period
      acquired.





In
      February 2004, the Company obtained a license from the University of Chicago
      for
      an adult stem cell technology. Costs associated with the acquisition of this
      license were originally accounted for as an intangible asset.  The
      amounts originally capitalized as intangible assets were $3,051,706, $976,497
      and $112,440 for the years ended December 31, 2004, 2005 and 2006 respectively.
      Upon further consideration of Paragraph 11(c) of SFAS No. 2, the Company
      determined that these assets had not reached technological feasibility at the
      date of acquisition and had no alternative future use. Therefore, the intangible
      asset should have been expensed to in process research and development in the
      period acquired.





In
      March
      2006, the Company obtained an exclusive worldwide license for the intellectual
      property rights and research results of an autologous T cell vaccine for
      rheumatoid arthritis from the Shanghai Institutes for Biological Sciences
      (SIBS), Chinese Academy of Sciences of the People's Republic of
      China.  The Company made a $125,000 license payment and accounted for
      the license as an intangible asset.  Upon further consideration of
      Paragraph 11(c) of SFAS No. 2, the Company determined that this asset had not
      reached technological feasibility at the date of acquisition and had no
      alternative future use. Therefore, the intangible asset should have been
      expensed to in process research and development in the period
      acquired.





In
      the
      Consolidated Statements of Expenses, the effect of the adjustments on operating
      expenses, loss from operations and net loss for each of the three months and
      six
      months ended June 30, 2006 and 2007 and January 22, 2003 (Inception) to June
      30,
      2007 was as follows:





-6-




**Three
                  Months Ended June 30,****2007**
              
              
              
              
              
              
              
              
              **2006****As
                  Reported**
              
              
              **Adjustment**
              
              
              **As
                  Restated**
              
              
              **As
                  Reported**
              
              
              **Adjustment**
              
              
              **As
                  Restated**Research
                  and development
              
              $
              3,712,208
              
              
              $
              -
              (1)
              
              $
              3,712,208
              
              
              $
              1,554,912
              
              
              $
              -
              (1)
              
              $
              1,554,912General
                  and administrative
              
              
              865,744
              
              
              
              -
              
              
              
              865,744
              
              
              
              3,169,832
              
              
              
              -
              
              
              $
              3,169,832Depreciation
                  and amortization
              
              
              462,370
              
              
              
              (412,275
              )(2)
              
              
              50,096
              
              
              
              460,442
              
              
              
              (410,846
              )(2)
              
              $
              49,596Loss
                  on disposal of assets
              
              
              4,034
              
              
              
              -
              
              
              
              4,034
              
              
              
              -
              
              
              
              -
              
              
              $
              -Operating
                  loss
              
              
              (5,044,356
              )
              
              
              412,275
              
              
              
              (4,632,082
              )
              
              
              (5,185,186
              )
              
              
              410,846
              
              
              
              (4,774,340
              )Interest
                  income
              
              
              141,971
              
              
              $
              -
              
              
              
              141,971
              
              
              
              198,785
              
              
              
              -
              
              
              $
              198,785Other
                  income
              
              
              -
              
              
              
              -
              
              
              
              -
              
              
              
              43,065
              
              
              
              -
              
              
              $
              43,065Gain
                  (loss) on derivative liability
              
              
              -
              
              
              
              -
              
              
              
              -
              
              
              
              (3,532,348
              )
              
              
              -
              
              
              $
              (3,532,348
              )Interest
                  expense
              
              
              (3,691
              )
              
              
              -
              
              
              
              (3,691
              )
              
              
              (184
              )
              
              
              -
              
              
              $
              (184
              )Net
                  loss
              
              $
              (4,906,076
              )
              
              $
              412,275
              
              
              $
              (4,493,802
              )
              
              $
              (8,475,868
              )
              
              $
              410,846
              
              
              $
              (8,065,022
              )Basic
                  and diluted loss per share
              
              $
              (0.73
              )
              
              $
              0.06
              
              
              $
              (0.67
              )
              
              $
              (1.40
              )
              
              $
              0.07
              
              
              $
              (1.34
              )










**Six
                  Months Ended June 30,****2007**
              
              
              
              
              
              
              
              
              **2006****As
                  Reported**
              
              
              **Adjustment**
              
              
              **As
                  Restated**
              
              
              **As
                  Reported**
              
              
              **Adjustment**
              
              
              **As
                  Restated**Research
                  and development
              
              $
              6,959,674
              
              
              $
              -
              (1)
              
              $
              6,959,674
              
              
              $
              2,293,362
              
              
              $
              125,000
              (1)
              
              $
              2,418,362General
                  and administrative
              
              
              1,715,530
              
              
              
              -
              
              
              
              1,715,530
              
              
              
              4,245,714
              
              
              
              -
              
              
              
              4,245,714Depreciation
                  and amortization
              
              
              923,476
              
              
              
              (824,551
              )(2)
              
              
              98,925
              
              
              
              892,775
              
              
              
              (820,129
              )(2)
              
              
              72,646Loss
                  on disposal of assets
              
              
              4,034
              
              
              
              -
              
              
              
              4,034
              
              
              
              362
              
              
              
              -
              
              
              
              362Operating
                  loss
              
              
              (9,602,714
              )
              
              
              824,551
              
              
              
              (8,778,163
              )
              
              
              (7,432,213
              )
              
              
              695,129
              
              
              
              (6,737,084
              )Interest
                  income
              
              
              320,794
              
              
              
              -
              
              
              
              320,794
              
              
              
              218,406
              
              
              
              -
              
              
              
              218,406Other
                  income
              
              
              -
              
              
              
              -
              
              
              
              -
              
              
              
              46,450
              
              
              
              -
              
              
              
              46,450Gain
                  (loss) on derivative liability
              
              
              -
              
              
              
              -
              
              
              
              -
              
              
              
              (3,278,208
              )
              
              
              -
              
              
              
              (3,278,208
              )Interest
                  expense
              
              
              (6,144
              )
              
              
              -
              
              
              
              (6,144
              )
              
              
              (613
              )
              
              
              -
              
              
              
              (613
              )Net
                  loss
              
              $
              (9,288,064
              )
              
              $
              824,551
              
              
              $
              (8,463,513
              )
              
              $
              (10,446,178
              )
              
              $
              695,129
              
              
              $
              (9,751,049
              )Basic
                  and diluted loss per share
              
              $
              (1.39
              )
              
              $
              0.12
              
              
              $
              (1.26
              )
              
              $
              (2.57
              )
              
              $
              0.17
              
              
              $
              (2.40
              )




**January
                  22, 2003 (Inception) to****June
                  30, 2007**As
                  Reported
              
              
              Adjustment
              
              
              As
                  RestatedResearch
                  and development
              
              $
              19,388,583
              
              
              $
              28,256,770
              (1)
              
              $
              47,645,353General
                  and administrative
              
              
              15,921,999
              
              
              
              -
              
              
              
              15,921,999Depreciation
                  and amortization
              
              
              4,742,299
              
              
              
              (4,358,118
              )(2)
              
              
              384,181Loss
                  on disposal of assets
              
              
              486,343
              
              
              
              -
              
              
              
              486,343Operating
                  loss
              
              
              (40,539,224
              )
              
              
              (23,898,652
              )
              
              
              (64,437,876
              )Interest
                  income
              
              
              1,097,015
              
              
              
              -
              
              
              
              1,097,015Other
                  income
              
              
              77,003
              
              
              
              -
              
              
              
              77,003Gain
                  (loss) on derivative liability
              
              
              -
              
              
              
              -
              
              
              
              -Interest
                  expense
              
              
              (8,245,107
              )
              
              
              -
              
              
              
              (8,245,107
              )Net
                  loss
              
              $
              (47,610,313
              )
              
              $
              (23,898,652
              )
              
              $
              (71,508,965
              )Basic
                  and diluted loss per share
              
              N/A
              
              
              N/A
              
              
              N/A




-7-
 
 (1)
                Adjustment
                    for capitalizing acquired research and development to intangible
                    assets
                    that should have been expensed to research and development (i)
                    for the
                    three months ended 6/30/2007 and 6/30/2006 in the amount of $-0-,
                    (ii) for
                    the six months ended 6/30/2007 in the amount of $-0- and for
                    the six
                    months ended 6/30/2006 in the amount of and $125,000 and (iii)
                    for the
                    period inception to 6/30/2007 in the amount of
                    $28,256,770.
 (2)
                Reversal
                    of amortization of intangible assets that should have been expensed
                    to
                    research and development (i) for the three months ended 6/30/2007
                    $412,275
                    and for the three months ended 6/30/2006 in the amount of $410,846,
                    (ii)
                    for the six months ended 6/30/2007 in the amount of $824,551
                    and for the
                    six months ended 6/30/2006 in the amount of $820,129 and  (iii)
                    inception to 6/30/2007 in the amount of
                    $4,358,118.
 In
            the
            Balance Sheet, the effect of the adjustments on Intangible Assets and
            Accumulated Deficit as of June 30, 2007 and December 31, 2006 was as
            follows:
  **June
                    30, 2007**
                
                
                
                
                
                **December
                    31, 2006****As
                    Reported**
                
                
                **Adjustment**
                
                
                **As
                    Restated**
                
                
                **As
                    Reported**
                
                
                **Adjustment**
                
                
                **As
                    Restated****Assets**Intangible
                    Assets
                
                $
                23,898,652
                
                
                $
                (23,898,652
                )(1)
                
                $
                -
                
                
                $
                24,723,203
                
                
                $
                (24,723,203
                )(1)
                
                $
                -**Stockholders'
                    Equity**Accumulated
                    Deficit
                
                $
                (47,610,313
                )
                
                $
                (23,898,652
                )(1)
                
                $
                (71,508,965
                )
                
                $
                (34,320,430
                )
                
                $
                (24,723,203
                )(1)
                
                $
                (59,043,633
                )


(1)Adjustment
      for
      capitalizing acquired research and development to intangible assets that should
      have been expensed to research and development, reversal of amortization of
      intangible assets that should have been expensed to research and development
      and
      reversal of impairment of intangible assets that should have been expensed
      to
      research and development.   Adjustments include:


a.
            Adjustment
                for capitalizing acquired research and development to intangible
                assets
                that should have been expensed to research and development as of
                6/30/2007
                in the amount of $28,256,771 and as of December 31, 2006 in the amount
                of
                $28,256,771.


b.
            Reversal
                of amortization of intangible assets that should have been expensed
                to
                research and development as of 6/30/2007 in the amount of $4,358,119
                and
                as of December 31, 2006 in the amount of
                $3,533,568.




**NOTE
      3– CASH AND CASH EQUIVALENTS**





Opexa
      considers all highly liquid investments with an original maturity of three
      months or less, when purchased, to be cash equivalents. Investments with
      maturities in excess of three months but less than one year are classified
      as
      short-term investments and are stated at fair market value.




The
      primary objectives for our fixed income investment portfolio are liquidity
      and
      safety of principal. Investments are made with the objective of achieving the
      highest rate of return consistent with these two objectives. Opexa’s investment
      policy limits investments to certain types of instruments issued by institutions
      primarily with investment grade credit ratings and places restrictions on
      maturities and concentration by type and issuer.




At
      June
      30, 2007, Opexa invested approximately $7.0 million in A-1/P-1 commercial paper
      with an average market yield of 5.38% and average time to maturity of less
      than
      one month. At June 30, 2007 $1.9 million was invested in a money market account
      with an average yield of 5.18%. Interest income of $320,794 was recognized
      for
      the six months ended June 30, 2007 in the statements of expenses.





**NOTE
      4 – COMMITMENTS**





In
      June
      2006, Opexa entered into an Individual Project Agreement (IPA) with PharmaNet,
      LLC, a contract research organization focused on managing central nervous system
      trials.  Pursuant to such IPA, PharmaNet, LLC will provide Opexa with
      services in connection with its Phase IIb clinical trial. Under the terms
      of the IPA, Opexa is required to advance funds in the amount of (i) $400,000
      for
      professional fees, (ii) $60,000 for out of pocket expenses and (iii) $175,000
      for investigator grants.   The fee advance is applied 1/12th per month
      to
      invoices and replenished once 75% depleted.  The out of pocket advance
      will be held and applied to the final invoice.  The investigator grant
      advance is used as a draw down advance and replenished once 75%
      depleted.  This process will continue until the end of the
      study.  In June 2007 Opexa made a replenishment advance of $175,000
      for investigator grants.  As of June 30, 2007 the advance balance to
      PharmaNet, LLC was $568,335.




-8-


**NOTE
      5 – LOAN PAYABLE**





Loan
      payable consists of an equipment line of up to $250,000 with Wells Fargo of
      which $247,608 was outstanding as of June 30, 2007. This loan has an interest
      rate of 7.61% per annum, matures in May 2011 and is secured by Opexa’s furniture
      and equipment purchased with the loan proceeds.  Approximately $91,000
      was drawn against the equipment line in the second quarter.





**NOTE
      6 – OPTIONS AND WARRANTS**





During
      the
      first quarter of 2007, Opexa issued 9,900 options to purchase common stock
      of
      Opexa to its new employees. These options are for a term of ten years, have
      an
      exercise price of $4.04 and vest over three years. Fair value of $36,805 was
      calculated using the Black-Scholes Model. Variables used in the Black-Scholes
      option-pricing model during the three months ended March 31, 2007, include
      (1)
      4.52% discount rate, (2) option life is the expected term of the options, (3)
      expected volatility of 103.91%, and (4) zero expected dividends. Option expense
      of $2,146 was recorded during the six months ended June 30, 2007.


During
      the
      second quarter of 2007, Opexa issued 209,000 options to purchase common stock
      of
      Opexa to its management and employees. These options are for a term of ten
      years, have an exercise price of $5.47 and vest over three years. Fair value
      of
      $858,098 was calculated using the Black-Scholes option-pricing model. Variables
      used in the Black-Scholes option-pricing model for options issued during the
      three months ended June 30, 2007, include (1) 5.07% discount rate, (2) option
      life is the expected term of the options, (3) expected volatility of 95.88%,
      and
      (4) zero expected dividends. A second quarter expense of $10,215 was
      recorded.





During
      the
      second quarter of 2007, Opexa issued 48,000 warrants to purchase common stock
      of
      Opexa to consultants and directors. These warrants are for a term of ten years,
      have an exercise price of $5.47 and have vesting dates that vary from either
      full or partial vesting at date of grant to full vesting at the one year
      anniversary of the date of grant. Fair value of $197,075 was calculated using
      the Black-Scholes option-pricing model. Variables used in the Black-Scholes
      option-pricing model for options issued during the three months ended June
      30,
      2007, include (1) 5.07% discount rate, (2) option life is the expected term
      of
      the options, (3) expected volatility of 95.88%, and (4) zero expected dividends.
      A second quarter expense of $92,164 was recorded.





**NOTE
      7 – DERIVATIVE INSTRUMENTS**




In
      June
      2006, Opexa evaluated the application of SFAS 133 and EITF 00-19 for all of
      its financial instruments and it was determined that certain of the warrants
      to
      purchase common stock issued by Opexa associated with the bridge note exchange
      and private placement offerings in June 2005 and July 2005 were derivatives
      that
      Opexa was required to account for as free-standing derivative instruments under
      GAAP.  These three series of warrants were considered at the time to be
      derivatives because the liquidated damage provision in the registration rights
      agreement covering each warrant resulted in the conclusion that it was more
      economic to issue registered shares than to issue unregistered shares and pay
      the penalty.  Because issuing registered shares is outside of Opexa’s
      control, Opexa concluded the warrants should be accounted for as derivative
      liabilities under SFAS 133 and EITF 00-19. As a result, Opexa reported the
      value
      of these derivatives as current liabilities on its balance sheet and reported
      changes in the value of these derivatives as non-operating gains or losses
      on
      its statements of operations in the consolidated financial statements beginning
      with the year ended December 31, 2005 and re-measured and reported on a
      quarterly basis thereafter based on the Black Scholes Pricing
      Model.





In
      December 2006, the FASB issued FASB Staff Position No. EITF 00-19-2, Accounting
      for Registration Payment Arrangements (EITF 00-19-2). EITF 00-19-2 addresses
      an
      issuer’s accounting for registration payment arrangements. It specifies that the
      contingent obligation to make future payments or otherwise transfer
      consideration under a registration payment arrangement, whether issued as a
      separate agreement or included as a provision of a financial instrument or
      other
      agreement, should be separately recognized and measured in accordance with
      FASB
      Statement No. 5, Accounting for Contingencies. The guidance in EITF 00-19-2
      amends FASB Statements No. 133, Accounting for Derivative Instruments and
      Hedging Activities, and No. 150, Accounting for Certain Financial
      Instruments with Characteristics of both Liabilities and Equity, and FASB
      Interpretation No. 45, Guarantor’s Accounting and Disclosure Requirements
      for Guarantees, including Indirect Guarantees of Indebtedness of Others, to
      include scope exceptions for registration payment arrangements. EITF 00-19-2
      also requires additional disclosure regarding the nature of any registration
      payment arrangements, alternative settlement methods, the maximum potential
      amount of consideration and the current carrying amount of the liability, if
      any. This EITF is effective immediately for registration payment arrangements
      and the financial instruments subject to those arrangements that are entered
      into or modified subsequent to the date of issue of this EITF. For registration
      payment arrangements and financial instruments subject to those arrangements
      that were entered into prior to the issuance of this EITF, this is effective
      for
      financial statements issued for fiscal years beginning after December 15, 2006,
      and interim periods within those fiscal years.





-9-


Opexa
      evaluated the application of EITF 00-19-2 for all its financial instruments
      and
      determined that certain warrants to purchase common stock issued by Opexa
      associated with the bridge note exchange and private placement offerings in
      June
      2005 and July 2005 no longer qualified to be classified as derivative
      liabilities.  In addition, Opexa accounts for registration rights
      agreement penalties as contingent liabilities, applying the accounting guidance
      of Financial Accounting Standard No. 5, “Accounting for Contingencies” (“FAS
      5”). This accounting is consistent with views established by the FASB Staff
      Positions FSP EITF 00-19-2 “Accounting for Registration Payment Arrangements”,
      which was issued December 21, 2006. Accordingly, Opexa recognizes the damages
      when it becomes probable that they will be incurred and amounts are reasonably
      estimable.





Certain
      4,600,000 shares of common stock and 2,513,720 warrants to purchase common
      stock
      are subject to a registration payment arrangement that provides if a resale
      registration statement is not effective for any period after April 13, 2007,
      the
      warrant holders may exercise their warrants on a cashless basis during the
      period the resale registration statement is not effective.  If Opexa
      fails to register, achieve effectiveness of registration or maintain
      effectiveness of registration of shares underlying the warrants and shares,
      they
      are required to make certain liquidated damage payments of 1.5% of the offering
      per month for every month in default with a maximum of 24%. Opexa does not
      believe these payments are probable and thus no contingent liability has been
      recorded.





Certain
      1,272,356 shares of common stock and 1,714,410 shares of common stock issuable
      upon the exercise of common stock purchase warrants issued in June 2005 and
      July
      2005 are subject to a registration payment arrangement that provides
      if a resale registration statement is not effective for any period after the
      first anniversary of the warrant, the warrant holders may exercise their
      warrants on a cashless basis during the period the resale registration statement
      is not effective.  If Opexa fails to register, achieve effectiveness
      of registration or maintain effectiveness of registration of shares underlying
      the warrants and shares, they are required to make certain liquidated damage
      payments of 1.0% of the offering per month for the first calendar month of
      registration default and 2%  for every month in default after the
      first month. Opexa does not believe these payments are probable and thus no
      contingent liability has been recorded.





The
      impact
      of implementing EITF 00-19-2 for the six months ended June 30, 2007 resulted
      in
      a cumulative effect of a change in accounting principle with a decrease in
      the
      derivative liability of $6,656,677 and a decrease to beginning retained earnings
      of $4,001,819 reversing gains posted to date and a reclassification of the
      original value of the warrants from liability to equity of
      $10,658,496.





**NOTE
      8 – SUBSEQUENT EVENTS**





***University
      of Chicago License Agreement***





In
      2004
      Opexa entered into an agreement with the University of Chicago (“University”)
      for the worldwide license to technology developed at Argonne National
      Laboratory, a U.S. Department of Energy Laboratory Operated by the University.
      In consideration for the license, Opexa paid the University $57,742 and issued
      237,188 shares valued at $1,199,706. In December 2004, the License Agreement
      was
      amended granting Opexa an exclusive, non-transferable worldwide license to
      the
      University’s stem cell technology. In consideration for the amendment, Opexa
      paid the University an additional $175,000, issued the University 5,500 shares
      of common stock valued at $352,000, agreed to pay the University $1,500,000
      on
      October 30, 2005 and agreed to issue the University  21,623 shares of
      Opexa common stock, including the shares already issued, equal to 2.6% of the
      total outstanding number of shares after conversion of the 15% exchangeable
      convertible subordinated promissory notes. In June 2005, 27,484 shares of common
      stock were issued to the University of Chicago per the terms of a license
      agreement. These shares were recorded at $867,064. In August 2005, 1,710 shares
      of common stock were issued to the University of Chicago per the terms of a
      license agreement. These shares were recorded at $109,434.  In April
      2007, the $1,500,000 cash payment obligation was extended until July 31, 2007
      and (ii) the obligation to issue shares of Opexa’s common stock issuable was
      extended until July 31, 2007, with $112,440 accrued at March 31, 2007. The
      Company determined that these assets had not reached technological feasibility
      at the date of acquisition and had no alternative future use. Therefore, the
      costs were expensed to research and development in the period
      incurred.





On
      July
      31, 2007, Opexa entered into a second amended and restated license agreement
      with the University of Chicago.  In consideration for the second
      amended and restated license agreement, Opexa is not obligated to make any
      further payments upon executing the second amendment and is no longer obligated
      to make the $1.5 million milestone payment that was due July 31, 2007 and
      accrued as a current liability as of June 30, 2007. Additionally, Opexa also
      is
      no longer obligated to issue 21,623 shares of its common stock, accrued as
      a
      current liability of $112,440 as of June 30, 2007 or any other securities to
      the
      University.  The second amended and restated license agreement
      includes payments to be made by Opexa to the University upon achieving certain
      future clinical development milestones.





-10-





**ITEM
      2.  MANAGEMENT'S DISCUSSION AND
      ANALYSIS**





*The
      following discussion of our financial condition and results of operations should
      be read in conjunction with the accompanying financial statements and the
      related footnotes thereto.*




**Forward-Looking
      Statements**





Some
      of
      the statements contained in this report discuss future expectations, contain
      projections of results of operations or financial condition, or state other
      "forward-looking" information. The words "believe," "intend," "plan," "expect,"
      "anticipate," "estimate," "project," "goal" and similar expressions identify
      such statement was made. These statements are subject to known and unknown
      risks, uncertainties, and other factors that could cause the actual results
      to
      differ materially from those contemplated by the statements. The forward-looking
      information is based on various factors and is derived using numerous
      assumptions. Factors that might cause or contribute to such a discrepancy
      include, but are not limited to the risks discussed in this and our other SEC
      filings. We do not promise to update forward-looking information to reflect
      actual results or changes in assumptions or other factors that could affect
      those statements. Future events and actual results could differ materially
      from
      those expressed in, contemplated by, or underlying such forward-looking
      statements.





The
      following discussion and analysis of our financial condition is as of June
      30,
      2007.  Our results of operations and cash flows should be read in
      conjunction with our unaudited financial statements and notes thereto included
      elsewhere in this report and the audited financial statements and the notes
      thereto included in our Form 10-KSB for the year ended December 31,
      2006.





**Business
      Overview**





Opexa
      Therapeutics, Inc. (the “Company”, “we”, “Opexa” or “Opexa Therapeutics”) is a
      biopharmaceutical company developing autologous cellular therapies to treat
      several major illnesses, including multiple sclerosis (MS), rheumatoid arthritis
      (RA), diabetes, and cardiovascular disease. These therapies are based on the
      Company’s proprietary T-cell and adult stem cell technologies.




Opexa
      Therapeutics’ lead product, Tovaxin®, is a T-cell based therapeutic vaccine for
      MS licensed from the Baylor College of Medicine, which offers a unique and
      personalized approach to treating the disease by inducing an immune response
      against the autoimmune myelin peptide-reactive T-cells (MRTCs), which are
      believed to be responsible for the initiation of the disease
      process.




Tovaxin
      is
      currently in a Phase IIb clinical trial. Initial Phase I/II open-label human
      trials show that T-cell vaccination (TCV) appears to safely induce immune
      responses that deplete and regulate MRTCs. In two open-label Phase I/II clinical
      trials, the annualized relapse rates of patients were reduced by an average
      of
      approximately 90% compared to their prior history of relapses.  Some
      patients also appear to experience an improvement of their Kurtzke Expanded
      Disability Status Scale, a scoring method used to measure the disability of
      MS
      patients (EDSS).  Improvements in EDSS are not frequently observed in
      patients following treatment with other currently licensed therapies. Although
      the data from our Phase I/II trials appears to be promising, the Phase IIb
      trial
      is being conducted to confirm these results. Opexa Therapeutics believes that
      Tovaxin could be ready for commercialization as early as 2011.




We
      also
      hold an exclusive worldwide license for the intellectual property rights and
      research results of an autologous T-cell vaccine for RA from the Shanghai
      Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the
      People's Republic of China.


Opexa’s
        RA
        T-cell vaccination (TCV) technology is conceptually similar to Tovaxin.RA
        is an
        autoimmune T-cell-mediated disease in which pathogenic T-cells trigger an
        inflammatory autoimmune response of the synovial joints of the wrists,
        shoulders, knees, ankles and feet which causes pain, stiffness, and swelling
        around the joints and erosion into cartilage and bone.  The RA TCV
        technology allows the isolation of these pathogenic T-cells from synovial
        fluid
        drawn from a patient.  These T-cells will be grown to therapeutic
        levels and attenuated by gamma irradiation in our laboratory.  The
        attenuated T-cells will be injected subcutaneously into patients thereby
        inducing an immune response directed at the pathogenic T-cells in the patient’s
        body.  This immune response regulates the level of pathogenic T-cells
        and potentially allows the reduction of joint swelling in RA patients. Human
        trials that have been conducted in China show minimal side-effects and promising
        efficacy measured as a reduction of joint swelling following the T-cell
        vaccination.
  We
        also
        have an exclusive license from the University of Chicago, through its prime
        contractor relationship with Argonne National Laboratory, to a stem cell
        technology in which adult multipotent stem cells are derived from monocytes
        (white blood cells) obtained from the patient’s own blood. We are initially
        pursuing indications in diabetes mellitus with our stem cell therapy and
        are
        conducting preclinical animal studies.


-11-


The
      Company’s stem cell technology isolates novel multipotent stem cells derived
      from peripheral blood monocytes. *In vitro* experiments with
      monocyte-derived stem cells (MDSC) have shown their capacity to differentiate
      into
      a
      wide variety of cell types including pancreatic β cells.  We have
      demonstratedthat these pancreatic islets clusters derived from MDSCs are
      composed of  three pancreatic cells types (a, b and d).
      These islet
      clusters are responsive to glucose and mimics the normal pulsatile pattern
      observed in human islets.****The importance of these stem
      cells is the ability to easily isolate them from an individual’s circulating
      monocytes, expand them and administer them back into the same patient. This
      autologous approach provides a method to overcome any rejection issues and
      the
      need for immunosuppressant drugs which are often associated with current islet
      cell transplantations. This technology may lead to the formation of an unlimited
      source of pancreatic islet cells suitable for an autologous cell therapy for
      the
      treatment of diabetes mellitus.




**Critical
      Accounting Policies**




***General***




The
      Financial Statements and Notes to Financial Statements contain information
      that
      is pertinent to this management’s discussion and analysis.  The
      preparation of financial statements in conformity with accounting principles
      generally accepted in the United States requires management to make estimates
      and assumptions that affect the reported amounts of assets and liabilities
      and
      disclosure of any contingent assets and liabilities.  Management
      believes these accounting policies involve judgment due to the sensitivity
      of
      the methods, assumptions and estimates necessary in determining the related
      asset and liability amounts.  Management believes it has exercised
      proper judgment in determining these estimates based on the facts and
      circumstances available to it at the time the estimates were
      made.  The significant accounting policies are described in the
      Company's financial statements.




**Results
      of Operations and Financial Condition**




*Three
      Months Ended June 30, 2007 Compared with the Three Months Ended June 30,
      2006*





**Net
      Sales.**We recorded no sales for the three months ended June
      30, 2007 and 2006.




**General
      and Administrative Expenses.**Our general and administrative expense was
      $865,744 for the three months ended June 30, 2007, as compared to $3,169,832
      for
      the three months ended June 30, 2006.  The decrease in expenses is
      primarily due to a decrease in stock compensation expenses, professional service
      fees and overhead expenses.  We anticipate increases in general and
      administrative expenses as we continue to develop and prepare for
      commercialization of our technology.




**Research
      and Development Expenses.**Research and development expense was
      $3,712,208 for the three months ended June 30, 2007, compared to $1,554,912
      for
      the three months ended June 30, 2006. The increase in expenses was primarily
      due
      to the costs of the Phase IIb clinical trial for Tovaxin, research and
      development in support of pre-clinical diabetes stem cell therapies and stock
      compensation expense recorded in 2007.  We have made and expect to
      continue to make substantial investments in research and development in order
      to
      develop and market our technology.  We expense research and
      development costs as incurred. Acquired research and development that has no
      alternative future use is expensed when acquired. We expect our research and
      development expense to increase as we continue to invest in the development
      of
      our technology.




**Interest
      Expense.**  Interest expense was $3,691for the three months
      ended June 30, 2007, compared to $184 for the three months ended June 30, 2006.
      The increase in interest expense was primarily due to a loan payable consisting
      of an equipment line of up to $250,000 with Wells Fargo of which $247,608 was
      outstanding as of June 30, 2007.




**Interest
      Income.**  Interest income was $141,971 for the three months
      ended June 30, 2007 compared to $198,785 for the three months ended June 30,
      2006.  The decrease was due to the reduction in cash balances that
      were available for investment in cash equivalent investments.




**Net
      loss.** We had a net loss for the three months ended June 30, 2007, of
      $4,493,802, or $0.67 per share (basic and diluted), compared with a net loss
      of
      $8,065,022, or $1.34 per share (basic and diluted), for the three months ended
      June 30, 2006. The decrease in net loss is primarily due to a reduction in
      stock-based compensation expense and loss on derivative instruments, offset
      in
      part by the increase in costs of the Phase IIb clinical trial for
      Tovaxin.




-12-




*Six
      Months Ended June 30, 2007 Compared with the Six Months Ended June 30,
      2006*





**Net
      Sales.**We recorded no sales for the six months ended June
      30, 2007 and 2006.




**General
      and Administrative Expenses.**General and administrative expense was
      $1,715,530 for the six months ended June 30, 2007, as compared to $4,245,714
      for
      the six months ended June 30, 2006.  The decrease in expenses is
      primarily due to a decrease in stock compensation expenses, professional service
      fees and overhead expenses.  We anticipate increases in general and
      administrative expenses as we continue to develop and prepare for
      commercialization of our technology.




**Research
      and Development Expenses.**Research and development expense was
      $6,959,674 for the six months ended June 30, 2007, compared to $,2,418,362
      for
      the six months ended June 30, 2006.   The increase in expenses
      was primarily due to the costs of the Phase IIb clinical trial for Tovaxin,
      research and development in support of pre-clinical diabetes stem cell therapies
      and stock compensation expense recorded in 2007.  We have made and
      expect to continue to make substantial investments in research and development
      in order to develop and market our technology.  We expense research
      and development costs as incurred. Acquired research and development that has
      no
      alternative future use is expensed when acquired. We expect our research and
      development expense to increase as we continue to invest in the development
      of
      our technology.




**Interest
      Expense.**  Interest expense was $6,144 for the six months
      ended June 30, 2007, compared to $613 for the six months ended June 30, 2006.
      The increase in interest expense was primarily due to a loan payable consisting
      of an equipment line of up to $250,000 with Wells Fargo of which $247,608 was
      outstanding as of June 30, 2007.




**Interest
      Income.**  Interest income was $320,794 for the six months
      ended June 30, 2007 compared to $218,406 for the six months ended June 30,
      2006.  The increase was due to the investment of the cash proceeds
      from the April 2006 equity financing in short term and cash equivalent
      investments.




**Net
      loss.** We had a net loss for the six months ended June 30, 2007, of
      $8,463,513, or $1.26 per share (basic and diluted), compared with a net loss
      of
      $9,751,049, or $2.40 per share (basic and diluted), for the six months ended
      June 30, 2006. The decrease in net loss is primarily due to a reduction in
      stock-based compensation expense and loss on derivative instruments, offset
      in
      part by the increase in costs of the Phase IIb clinical trial for
      Tovaxin.




**Liquidity
      and Capital Resources**




**Changes
      in cash flow.**Cash used in operations for the six month
      period ended June 30, 2007 was $3,126,508, as compared to $3,452,658 used in
      operations for the six months ended June 30, 2006. The decrease in cash used
      in
      operations is primarily due to the maturity of approximately $2.9 million in
      marketable securities and its reclassification to cash and cash equivalents
      and
      by an increase in accrued expenses resulting from the Phase IIb clinical trial,
      offset in part by an increase in operating expenses.  Cash used in
      investing activities for the six month period ended June 30, 2007 was $112,591,
      as compared to $340,229 for the six months ended June 30, 2006.  The
      decrease was primarily due to the license payment made to Shanghai Institute
      related to the license obtained during the six months ended June 30, 2006 for
      its rheumatoid arthritis T-cell technology and a decrease in equipment
      purchases. Cash provided from financing activities for the six month period
      ended June 30, 2007 was $137,286, as compared to $21,163,763 for the six months
      ended June 30, 2006. The decrease was due to the proceeds from the April 2006
      equity financing.





**Liquidity**.  Historically,
      the Company has financed its operations primarily from the sale of its debt
      and
      equity securities.  As of June 30, 2007, the Company had cash, cash
      equivalents and marketable securities of approximately $9 million.




Our
      current burn rate is approximately $1,000,000 per month excluding capital
      expenditures.  We will need to raise additional capital to fund our working
      capital needs beyond the first quarter of 2008.  We must rely upon
      best efforts third-party debt or equity funding and we can provide no assurance
      that we will be successful in any funding effort. The failure to raise such
      funds will necessitate the curtailment of operations and impact the completion
      of the clinical trials.




**Off-Balance
      Sheet Arrangements**





As
      of June 30, 2007, we had no
      off-balance sheet arrangements.





**Recent
      Accounting Pronouncements**





-13-


For
      the
      period ended June 30, 2007, there were no other changes to our critical
      accounting policies as identified in our annual report of Form 10-KSB for the
      year ended December 31, 2006.





**Risk
      Factors**





The
      following factors affect our
      business and the industry in which we operate. The risks and uncertainties
      described below are not the only ones we face. Additional risks and
      uncertainties not presently known or which we currently consider immaterial
      may
      also have an adverse effect on our business. If any of the matters discussed
      in
      the following risk factors were to occur, our business, financial condition,
      results of operations, cash flows, or prospects could be materially adversely
      affected.




***Our
      business is at an early stage of development.***




Our
      business is at an early stage of development. We do not have any products in
      late-stage clinical trials or on the market. We are still in the early stages
      of
      identifying and conducting research on potential products. Only one of our
      products has progressed to the stage of being studied in human clinical trials
      in the U.S.  Our potential products will require significant research
      and development and preclinical and clinical testing prior to regulatory
      approval in the United States and other countries. We may not be able to develop
      any products, to obtain regulatory approvals, to enter clinical trials for
      any
      of our product candidates, or to commercialize any products. Our product
      candidates may prove to have undesirable and unintended side effects or other
      characteristics adversely affecting their safety, efficacy or cost-effectiveness
      that could prevent or limit their use. Any product using any of our technology
      may fail to provide the intended therapeutic benefits, or achieve therapeutic
      benefits equal to or better than the standard of treatment at the time of
      testing or production.




***We
      have a history of operating losses and do not expect to be profitable in the
      near future.***




We
      have
      not generated any profits since our entry into the biotechnology business,
      have
      no source of revenues, and have incurred significant operating losses. We expect
      to incur additional operating losses for the foreseeable future and, as we
      increase our research and development activities, we expect our operating losses
      to increase significantly. We do not have any sources of revenues and may not
      have any in the foreseeable future.




***We
      will need additional capital to conduct our operations and develop our products
      and our ability to obtain the necessary funding is
      uncertain.***




We
      need to
      obtain significant additional capital resources from sources including equity
      and/or debt financings, license arrangements, grants and/or collaborative
      research arrangements in order to develop products and continue our
      business.  As of June 30, 2007, we had cash, cash equivalents and
      marketable securities of approximately $9 million. Our current burn rate is
      approximately $1,000,000 per month excluding capital expenditures. We will
      need to raise additional capital to fund our working capital needs beyond first
      quarter 2008.  We must rely upon best efforts third-party debt or
      equity funding and we can provide no assurance that we will be successful in
      any
      funding effort. The failure to raise such funds will necessitate the curtailment
      of operations and impact the completion of the clinical trials.




The
      timing and degree of any future capital requirements will depend on many
      factors, including:




·
            scientific
                progress in our research and development
                programs;





·
            the
                accuracy of the assumptions underlying our estimates for capital
                needs in
                2007 and beyond;




·
            the
                magnitude and scope of our research and development
                programs;




·
            our
                ability to establish, enforce and maintain strategic arrangements
                for
                research, development, clinical testing, manufacturing and
                marketing;




·
            our
                progress with preclinical development and clinical
                trials;




·
            the
                time and costs involved in obtaining regulatory
                approvals;




·
            the
                costs involved in preparing, filing, prosecuting, maintaining, defending
                and enforcing patent claims; and




·
            the
                number and type of product candidates that we
                pursue.




-14-


We
      do not
      have any committed sources of capital, although we have issued and outstanding
      warrants that, if exercised, would result in an equity capital raising
      transaction.  Additional financing through strategic collaborations,
      public or private equity financings, capital lease transactions or other
      financing sources may not be available on acceptable terms, or at all.
      Additional equity financings could result in significant dilution to our
      stockholders. Further, if additional funds are obtained through arrangements
      with collaborative partners, these arrangements may require us to relinquish
      rights to some of our technologies, product candidates or products that we
      would
      otherwise seek to develop and commercialize ourselves. If sufficient capital
      is
      not available, we may be required to delay, reduce the scope of or eliminate
      one
      or more of our programs, any of which could have a material adverse effect
      on
      our financial condition or business prospects.




***Clinical
      trials are subject to extensive regulatory requirements, very expensive,
      time-consuming and difficult to design and implement.  Our products
      may fail to achieve necessary safety and efficacy endpoints during clinical
      trials.***




Human
      clinical trials are very expensive and difficult to design and implement, in
      part because they are subject to rigorous regulatory requirements. The clinical
      trial process is also time consuming. We estimate that clinical trials of our
      product candidates will take at least several years to complete. Furthermore,
      failure can occur at any stage of the trials, and we could encounter problems
      that cause us to abandon or repeat clinical trials. The commencement and
      completion of clinical trials may be delayed by several factors,
      including:




·
            unforeseen
                safety issues;




·
            determination
                of dosing issues;




·
            lack
                of effectiveness during clinical
                trials;




·
            slower
                than expected rates of patient
                recruitment;




·
            inability
                to monitor patients adequately during or after treatment;
                and




·
            inability
                or unwillingness of medical investigators to follow our clinical
                protocols.




In
      addition, we or the FDA may suspend our clinical trials at any time if it
      appears that we are exposing participants to unacceptable health risks or if
      the
      FDA finds deficiencies in our IND submissions or the conduct of these
      trials.




***We
      are dependent upon our management team and a small number of
      employees.***




Our
      business strategy is dependent upon the skills and knowledge of our management
      team.  We believe that the special knowledge of these individuals
      gives us a competitive advantage.  If any critical employee leaves, we
      may be unable on a timely basis to hire suitable replacements to effectively
      operate our business.  We also operate with a very small number of
      employees and thus have little or no backup capability for their
      activities.  The loss of the services of any member of our management
      team or the loss of a number of other employees could have a material adverse
      effect on our business.




***We
      are dependent on contract research organizations and other contractors for
      clinical testing and for certain research and development activities, thus
      the
      timing and adequacy of our clinical trials and such research activities are,
      to
      a certain extent, beyond our control.***




The
      nature
      of clinical trials and our business strategy requires us to rely on contract
      research organizations, independent clinical investigators and other third
      party
      service providers to assist us with clinical testing and certain research and
      development activities. As a result, our success is dependent upon the success
      of these outside parties in performing their responsibilities. Although we
      believe our contractors are economically motivated to perform on their
      contractual obligations, we cannot directly control the adequacy and timeliness
      of the resources and expertise applied to these activities by our contractors.
      If our contractors do not perform their activities in an adequate or timely
      manner, the development and commercialization of our drug candidates could
      be
      delayed.




***Our
      current research and manufacturing facility is not large enough to manufacture
      future stem cell and T-cell therapies.***




We
      conduct
      our research and development in a 10,200 square foot facility in The Woodlands,
      Texas, which includes an approximately 800 square foot suite of three rooms
      for
      the manufacture of stem cell and T-cell therapies through Phase III
      trials.  Our current facility is not large enough to conduct
      commercial-scale manufacturing operations.  We will need to expand
      further our manufacturing staff and facility, obtain a new facility or contract
      with corporate collaborators or other third parties to assist with future drug
      production.




-15-


In
      the
      event that we decide to establish a commercial-scale manufacturing facility,
      we
      will require substantial additional funds and will be required to hire and
      train
      significant numbers of employees and comply with applicable regulations, which
      are extensive. We do not have funds available for building a manufacturing
      facility, and we may not be able to build a manufacturing facility that both
      meets regulatory requirements and is sufficient for our commercial-scale
      manufacturing.




We
      may
      arrange with third parties for the manufacture of our future products. However,
      our third-party sourcing strategy may not result in a cost-effective means
      for
      manufacturing our future products.  If we employ third-party
      manufacturers, we will not control many aspects of the manufacturing process,
      including compliance by these third parties with the FDA’s current Good
      Manufacturing Practices and other regulatory requirements. We further may not
      be
      able to obtain adequate supplies from third-party manufacturers in a timely
      fashion for development or commercialization purposes, and commercial quantities
      of products may not be available from contract manufacturers at acceptable
      costs.




***Patents
      obtained by other persons may result in infringement claims against us that
      are
      costly to defend and which may limit our ability to use the disputed
      technologies and prevent us from pursuing research and development or
      commercialization of potential products.***




A
      number
      of pharmaceutical, biotechnology and other companies, universities and research
      institutions have filed patent applications or have been issued patents relating
      to cell therapy, stem cells, T-cells, and other technologies potentially
      relevant to or required by our expected products. We cannot predict which,
      if
      any, of such applications will issue as patents or the claims that might be
      allowed. We are aware that a number of companies have filed applications
      relating to stem cells. We are also aware of a number of patent applications
      and
      patents claiming use of stem cells and other modified cells to treat disease,
      disorder or injury.




If
      third
      party patents or patent applications contain claims infringed by either our
      licensed technology or other technology required to make and use our potential
      products and such claims are ultimately determined to be valid, there can be
      no
      assurance that we would be able to obtain licenses to these patents at a
      reasonable cost, if at all, or be able to develop or obtain alternative
      technology. If we are unable to obtain such licenses at a reasonable cost,
      we
      may not be able to develop some products commercially. There can be no assurance
      that we will not be obliged to defend ourselves in court against allegations
      of
      infringement of third party patents. Patent litigation is very expensive and
      could consume substantial resources and create significant uncertainties. An
      adverse outcome in such a suit could subject us to significant liabilities
      to
      third parties, require disputed rights to be licensed from third parties, or
      require us to cease using such technology.




***If
      we are unable to obtain future patents and other proprietary rights our
      operations will be significantly harmed.***




Our
      ability to compete effectively is dependent in part upon obtaining patent
      protection relating to our technologies. The patent positions of pharmaceutical
      and biotechnology companies, including ours, are uncertain and involve complex
      and evolving legal and factual questions. The coverage sought in a patent
      application can be denied or significantly reduced before or after the patent
      is
      issued. Consequently, we do not know whether the patent applications for our
      technology will result in the issuance of patents, or if any future patents
      will
      provide significant protection or commercial advantage or will be circumvented
      by others. Since patent applications are secret until the applications are
      published (usually eighteen months after the earliest effective filing date),
      and since publication of discoveries in the scientific or patent literature
      often lags behind actual discoveries, we cannot be certain that the inventors
      of
      our licensed patents were the first to make the inventions covered by the patent
      applications or that the licensed patent applications were the first to be
      filed
      for such inventions. There can be no assurance that patents will issue from
      the
      patent applications or, if issued, that such patents will be of commercial
      benefit to us, afford us adequate protection from competing products, or not
      be
      challenged or declared invalid.




***Our
      competition includes fully integrated biopharmaceutical and pharmaceutical
      companies that have significant advantages over us.***




The
      markets for therapeutic stem cell products, multiple sclerosis products, and
      rheumatoid arthritis products are highly competitive. We expect that our most
      significant competitors are fully integrated pharmaceutical companies and more
      established biotechnology companies. These companies are developing stem
      cell-based products and they have significantly greater capital resources and
      expertise in research and development, manufacturing, testing, obtaining
      regulatory approvals, and marketing than we currently do. Many of these
      potential competitors are further along in the process of product development
      and also operate large, company-funded research and development programs. As
      a
      result, our competitors may develop more competitive or affordable products,
      or
      achieve earlier patent protection or product commercialization than we are
      able
      to achieve. Competitive products may render any products or product candidates
      that we develop obsolete.




-16-


***If
      we fail to meet our obligations under our license agreements, we may lose our
      rights to key technologies on which our business
      depends.***




Our
      business depends on three licenses from third parties. These third party license
      agreements impose obligations on us, such as payment obligations and obligations
      to diligently pursue development of commercial products under the licensed
      patents. If a licensor believes that we have failed to meet our obligations
      under a license agreement, the licensor could seek to limit or terminate our
      license rights, which could lead to costly and time-consuming litigation and,
      potentially, a loss of the licensed rights. During the period of any such
      litigation, our ability to carry out the development and commercialization
      of
      potential products could be significantly and negatively affected. If our
      license rights were restricted or ultimately lost, our ability to continue
      our
      business based on the affected technology platform could be severely adversely
      affected.




***Restrictive
      and extensive government regulation could slow or hinder our production of
      a
      cellular product.***




The
      research and development of stem cell therapies is subject to and restricted
      by
      extensive regulation by governmental authorities in the United States and other
      countries. The process of obtaining U.S. Food and Drug Administration, or FDA,
      and other necessary regulatory approvals is lengthy, expensive and uncertain.
      We
      may fail to obtain the necessary approvals to continue our research and
      development, which would hinder our ability to manufacture or market any future
      product.




***To
      be successful, our product candidates must be accepted by the health care
      community, which can be very slow to adopt or unreceptive to new technologies
      and products.***




Our
      product candidates, if approved for marketing, may not achieve market acceptance
      since hospitals, physicians, patients or the medical community in general may
      decide to not accept and utilize these products. The product candidates that
      we
      are attempting to develop represent substantial departures from established
      treatment methods and will compete with a number of more conventional drugs
      and
      therapies manufactured and marketed by major pharmaceutical companies. The
      degree of market acceptance of any of our developed products will depend on
      a
      number of factors, including:




·
            our
                establishment and demonstration to the medical community of the clinical
                efficacy and safety of our product
                candidates;





·
            our
                ability to create products that are superior to alternatives currently
                on
                the market;





·
            our
                ability to establish in the medical community the potential advantage
                of
                our treatments over alternative treatment methods;
                and





·
            reimbursement
                policies of government and third-party
                payers.




If
      the
      health care community does not accept our products for any of the foregoing
      reasons, or for any other reason, our business would be materially
      harmed.




***There
      is currently a limited market for
      our common stock, andany
      trading market that exists in our common stock may be highly illiquid and may
      not reflect the underlying value of the Company’s net assets or business
      prospects.***




Although
      our common stock is traded on the Nasdaq Global Market, there is currently
      a
      limited market for our common stock and there can be no assurance that an
      improved market will ever develop.  Investors are cautioned not to
      rely on the possibility that an active trading market may develop.




***As
      our share price is volatile, we may be or become the target of securities
      litigation, which is costly and time-consuming to
      defend.***




In
      the
      past, following periods of market volatility in the price of a company’s
      securities or the reporting of unfavorable news, security holders have often
      instituted class action litigation. If the market value of our common stock
      experiences adverse fluctuations and we become involved in this type of
      litigation, regardless of the outcome, we could incur substantial legal costs
      and our management’s attention could be diverted from the operation of our
      business, causing our business to suffer.




***Our
      "blank check" preferred stock could be issued to prevent a business combination
      not desired by management or our current majority
      shareholders.***




-17-


Our
      articles of incorporation authorize the issuance of "blank check" preferred
      stock with such designations, rights and preferences as may be determined by
      our
      board of directors without shareholder approval. Our preferred stock could
      be
      utilized as a method of discouraging, delaying, or preventing a change in our
      control and as a method of preventing shareholders from receiving a premium
      for
      their shares in connection with a change of control.




***Future
      sales of our common stock in the public market could lower our stock
      price.***




We
      may
      sell additional shares of common stock in subsequent public or private
      offerings. We may also issue additional shares of common stock to finance future
      acquisitions. We cannot predict the size of future issuances of our common
      stock
      or the effect, if any, that future issuances and sales of shares of our common
      stock will have on the market price of our common stock. Sales of substantial
      amounts of our common stock (including shares issued in connection with an
      acquisition), or the perception that such sales could occur, may adversely
      affect prevailing market prices for our common stock.




***We
      presently do not intend to pay cash
      dividends on our common stock.***




We
      currently anticipate that no cash dividends will be paid on the common stock
      in
      the foreseeable future. While our dividend policy will be based on the operating
      results and capital needs of the business, it is anticipated that all earnings,
      if any, will be retained to finance the future expansion of the our
      business.







**ITEM
      3. CONTROLS AND PROCEDURES**





**(a)**
            **Evaluation
                of Disclosure Controls and
                Procedures.**





We
      maintain disclosure controls and procedures that are designed to ensure that
      information required to be disclosed by us in the reports that we file or submit
      to the Securities and Exchange Commission under the Securities Exchange Act
      of
      1934, as amended, is recorded, processed, summarized, and reported within the
      time periods specified by the Securities and Exchange Commission’s rules and
      forms, and that information is accumulated and communicated to our management,
      including our principal executive and principal financial officers (whom we
      refer to in this periodic report as our Certifying Officers), as appropriate
      to
      allow timely decisions regarding required disclosure. Our management evaluated,
      with the participation of our Certifying Officers, the effectiveness of our
      disclosure controls and procedures as of June 30, 2007, pursuant to
      Rule 13a-15(b) under the Securities Exchange Act. Based upon that
      evaluation, our Certifying Officers concluded that, as of June 30, 2007, our
      disclosure controls and procedures were not effective for the reason described
      below:





In
      connection with receiving comments from the Securities & Exchange Commission
      regarding our Annual Report on form 10-KSB filed March 16 2007, we reviewed
      the
      appropriateness of the capitalization of certain costs of acquiring various
      intellectual property rights versus treatment of such costs as a period expense
      for the period in which such rights were acquired. We identified deficiencies
      in
      our internal controls and disclosure controls related to the accounting for
      acquired research and development in accordance with Paragraph 11(c) of
      Statement of Financial Accounting Standards No. 2 (SFAS No. 2) and accounting
      guidance from Financial Accounting Standards Board Interpretation No. 4
“Applicability of FASB Statement No. 2 to Business Combinations Accounted for
      by
      the Purchase Method” (FIN 4). We restated our consolidated financial statements
      for the year ended December 31, 2006 and for the interim periods ending March
      31, 2007, June 30, 2007 and June 30, 2007, in order to correct the accounting
      in
      such financial statements with respect to acquired research and development
      that
      has no alternative future use. Since November 2007, we have undertaken
      improvements to our internal controls in an effort to remediate these
      deficiencies by improving supervision and training of our accounting staff
      to
      understand and implement the requirements of complex accounting
      issues.  We have also adopted a policy whereby financial management,
      when dealing with the reporting of transactions that involve complex and unusual
      accounting matters, will formally research relevant accounting literature
      relating to the issues and, if necessary, retain the services of a qualified
      certified public accountant, other than our independent auditor, to assist
      us
      with respect to accounting for the transaction(s).








**(b)**
            **Changes
                in Internal Control Over Financial
                Reporting.**





There
      were
      changes in our internal control over financial reporting that occurred during
      our most recently completed fiscal year that have materially affected, or are
      reasonably likely to materially affect, our internal control over financial
      reporting.  We will continue to evaluate the effectiveness of internal
      controls and procedures on an on-going basis.





-18-


**PART
      II**




**OTHER
      INFORMATION**





**ITEM
      1. LEGAL PROCEEDINGS.**





None.





**ITEM
      2. UNREGISTERED SALES OF EQUITY SECURITIES
      AND USE OF
      PROCEEDS.**





None.





**ITEM
      3 DEFAULTS UPON SENIOR SECURITIES.**





None.





**ITEM
      4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY
      HOLDERS.**





**(a)  Annual
      Meeting of Shareholders.**





On
      June 18, 2007 the Company held its
      2006 Annual Meeting of Shareholders and the shareholders approved several items
      detailed in the Proxy Statement previously filed with the
      Commission.





**(b)   Election
      of Board of Directors.**





The
      following nominees were elected by
      the shareholders at the 2006 Annual Meeting:


Gregory
      Bailey - Director


David
      Hung - Director


David
      B.
      McWilliams -
      Director


Michael
      Richman -
      Director


Scott
      Seaman - Director





**(c)**
            **Proposals
                Voted Upon and Shareholder
                Vote.**





The
      shareholders voted to (i) elect
      five (5) Directors to the Company's Board of Directors to hold office until
      the
      next annual meeting of shareholders or until their respective successors are
      duly elected and qualified and ratify the selection by the Audit Committee
      of
      Malone & Bailey, PC as the independent auditors of the Company for the
      fiscal year ending December 31, 2007.  A total of 3,539,231shares were
      voted representing 53% of the outstanding shares.  The votes cast for
      and against each of the above-described three proposals are listed in the tables
      below.




**Proposal
      #1 - Election of Each of the Nominated Directors:**




**Election
                  of Directors**
              **For**
              **Against**
              **Abstain**David
                  B. McWilliams
              3,516,685
              22,546
              -0-Gregory
                  Bailey
              3,374,727
              164,504
              -0-David
                  Hung
              3,536,068
              3,163
              -0-Michael
                  Richman
              3,536,068
              3,163
              -0-Scott
                  Seaman
              3,536,068
              3,163
              -0-




**Proposal
      #2 - Ratification of Appointment of Auditor:**




**For**
              **Against**
              **Abstain**3,536,112
              1,107
              2,012




-19-






**ITEM
      5. OTHER INFORMATION.**





None.







**ITEM
      6. EXHIBITS.**




Exhibit
                  31.1
              Chief
                  Executive Officer Certification Pursuant to Section 13a-14 of the
                  Securities Exchange Act (1)Exhibit
                  31.2
              Chief
                  Financial Officer Certification Pursuant to Section 13a-14 of the
                  Securities Exchange Act (1)Exhibit
                  32.1
              Certification
                  Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section
                  906 of
                  theSarbanes-
                  Oxley Act of 2002 (1)Exhibit
                  32.2
              Certification
                  Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section
                  906 of
                  theSarbanes-
                  Oxley Act of 2002 (1)




(1)  Filed
      herewith.








**SIGNATURES**





In
      accordance with Section 13 or 15(d) of the Exchange Act, the registrant has
      caused this report to be signed on its behalf by the undersigned, thereunto
      duly
      authorized.






**OPEXA
              THERAPEUTICS, INC.**By:
            /s/ David
              B. McWilliamsDavid
              B. McWilliams,President
              and Chief Executive Officer


Date:
                November 29, 2007
            By:
            /s/ Lynne
              HohlfeldLynne
              HohlfeldChief
              Financial Officer and Principal Accounting Officer









-20-